OverT Bio moves OVT-101 closer to clinic as solid tumour cell therapy race intensifies
OverT Bio is advancing OVT-101 toward the clinic in ovarian cancer. Read what its new advisory board could change for solid tumour cell therapy.
OverT Bio is advancing OVT-101 toward the clinic in ovarian cancer. Read what its new advisory board could change for solid tumour cell therapy.